Chronic Myeloid Leukemia Treatment Market Perspective by Comprehensive Analysis Growth Prediction to 2026
Chronic Myeloid Leukemia Treatment Market Drivers
Increasing number of researches that are being carried out to identify the causes of CML cancer is expected to boost growth of the chronic myeloid leukemia treatment market over the forecast period. Targeted drug known as tyrosine-kinase inhibitors (TKIs) have been effective in providing long-term survival rates. Furthermore, the Food and Drug Administration (FDA) approved dasatinib (Sprycel) for the treatment of chronic myeloid leukemia in pediatrics in 2017. Researchers are also focusing on polypharmacology approach to develop drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’.
As chronic myeloid leukemia is more aggressive in younger patients, the approval of drugs can help in effective treatment. Moreover, with the development of imatinib and the second generation TKIs, dasatinib and nilotinib, small molecule drugs have become the mainstay for the first-line CML management. However, high cost of the drugs used for this disease is a major restraint affecting the growth of the market. For instance, TKIs drugs are very expensive and therefore, generic drugs are being introduced in various countries. Increasing prevalence of this cancer in various regions is expected to drive growth of the market over the forecast period. For instance, according to an article published in UBM Medica LLC, CML accounts for around 15% of the total leukemia cases in adults. Approximately 8,220 new cases of CML were diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 population.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a blood-cell cancer that begins in the blood-forming cells of the bone marrow. Myeloid cells are a type of immature cells that are capable of making white blood cells and when these cells continue to grow in an abnormal condition, it turns into a chronic myeloid leukemia condition. This cancer majorly causes fatigue, fever, easy bleeding, infection, bone pain, anemia, and swollen spleen among the patients who are middle-aged people or older, though it can occur in children also.
To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/ongoing-insight/toc/1726
CML is a slowly growing leukemia, however, it can also change into a fast-growing acute leukemia, which is harder to treat. Continuous support from the government by approving the pipeline drugs for CML is expected to propel growth of the market over the forecast period. For instance, in February 2014, Teva Pharmaceutical Industries Ltd.’s drug, SYNRIBO (omacetaxine mepesuccinate) for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) got the U.S. FDA approval.
You may be interested
Lipid Testing Market Upcoming Trends and Overview Forecast till 2026Albert R - December 17, 2018
Lipid Testing Market Report 2018 look into the study is an exceptionally tenacious examination on aggressive scene investigation, prime makers, showcasing procedures examination, Market Effect Factor Analysis…
Refinery Catalyst Market Volume Forecast and Value Chain Analysis 2018 to 2026Mohit Joshi - December 17, 2018
Refinery Catalyst Market Report 2018 look into the study is an exceptionally tenacious examination on aggressive scene investigation, prime makers, showcasing procedures examination, Market Effect Factor Analysis…
Childhood Absence Epilepsy Treatment Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026Rachel Stinson - December 17, 2018
Childhood Absence Epilepsy Treatment Market Report 2018 look into the study is an exceptionally tenacious examination on aggressive scene investigation, prime makers, showcasing procedures examination, Market Effect…